These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 26686787)

  • 1. Estimating a Preference-Based Index for an Eight-Dimensional Health State Classification System for Multiple Sclerosis.
    Goodwin E; Green C; Spencer A
    Value Health; 2015 Dec; 18(8):1025-36. PubMed ID: 26686787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health State Values Derived from People with Multiple Sclerosis for a Condition-Specific Preference-Based Measure: Multiple Sclerosis Impact Scale-Eight Dimensions-Patient Version (MSIS-8D-P).
    Goodwin E; Green C; Hawton A
    Value Health; 2018 Nov; 21(11):1338-1345. PubMed ID: 30442282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Quality-Adjusted Life-Year Measure for Multiple Sclerosis: Developing a Patient-Reported Health State Classification System for a Multiple Sclerosis-Specific Preference-Based Measure.
    Goodwin E; Green C
    Value Health; 2015 Dec; 18(8):1016-24. PubMed ID: 26686786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Difference Does It Make? A Comparison of Health State Preferences Elicited From the General Population and From People With Multiple Sclerosis.
    Goodwin E; Green C; Hawton A
    Value Health; 2020 Feb; 23(2):242-250. PubMed ID: 32113630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the Fatigue Severity Scale to inform healthcare decision-making in multiple sclerosis: mapping to three quality-adjusted life-year measures (EQ-5D-3L, SF-6D, MSIS-8D).
    Goodwin E; Hawton A; Green C
    Health Qual Life Outcomes; 2019 Aug; 17(1):136. PubMed ID: 31382960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Naming and Framing": The Impact of Labeling on Health State Values for Multiple Sclerosis.
    Green C; Goodwin E; Hawton A
    Med Decis Making; 2017 Aug; 37(6):703-714. PubMed ID: 28528557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis health-related quality of life utility values from the UK MS register.
    Heather A; Goodwin E; Green C; Morrish N; Ukoumunne OC; Middleton RM; Hawton A
    Mult Scler J Exp Transl Clin; 2023; 9(2):20552173231178441. PubMed ID: 37324245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deriving a Preference-Based Measure for Myelofibrosis from the EORTC QLQ-C30 and the MF-SAF.
    Mukuria C; Rowen D; Brazier JE; Young TA; Nafees B
    Value Health; 2015 Sep; 18(6):846-55. PubMed ID: 26409613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric properties of quality of life and health-related quality of life assessments in people with multiple sclerosis.
    Learmonth YC; Hubbard EA; McAuley E; Motl RW
    Qual Life Res; 2014 Sep; 23(7):2015-23. PubMed ID: 24526294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Validation of selected aspects of psychometry of the Polish version of the Multiple Sclerosis Impact Scale 29 (MSIS-29)].
    Jamroz-Wiśniewska A; Papuć E; Bartosik-Psujek H; Belniak E; Mitosek-Szewczyk K; Stelmasiak Z
    Neurol Neurochir Pol; 2007; 41(3):215-22. PubMed ID: 17629814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis.
    Versteegh M
    Pharmacoeconomics; 2016 Nov; 34(11):1133-1144. PubMed ID: 27282692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using existing data to identify candidate items for a health state classification system in multiple sclerosis.
    Kuspinar A; Finch L; Pickard S; Mayo NE
    Qual Life Res; 2014 Jun; 23(5):1445-57. PubMed ID: 24338161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29.
    Rosti-Otajärvi E; Hämäläinen P; Wiksten A; Hakkarainen T; Ruutiainen J
    Brain Behav; 2017 Jul; 7(7):e00725. PubMed ID: 28729932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.
    Hawton A; Green C; Telford CJ; Wright DE; Zajicek JP
    Mult Scler; 2012 Jun; 18(6):853-61. PubMed ID: 22108867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use.
    van der Linden FA; Kragt JJ; Klein M; van der Ploeg HM; Polman CH; Uitdehaag BM
    J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1677-81. PubMed ID: 16291893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.
    Hobart JC; Riazi A; Lamping DL; Fitzpatrick R; Thompson AJ
    Health Technol Assess; 2004 Mar; 8(9):iii, 1-48. PubMed ID: 14982653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.
    McGuigan C; Hutchinson M
    J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):266-9. PubMed ID: 14742602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study.
    Giordano A; Pucci E; Naldi P; Mendozzi L; Milanese C; Tronci F; Leone M; Mascoli N; La Mantia L; Giuliani G; Solari A
    J Neurol Neurosurg Psychiatry; 2009 Sep; 80(9):1023-8. PubMed ID: 19443471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
    Hobart J; Lamping D; Fitzpatrick R; Riazi A; Thompson A
    Brain; 2001 May; 124(Pt 5):962-73. PubMed ID: 11335698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.